Navigation Links
Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
Date:6/8/2009

, Weston Park Hospital, Shefield.

About Pixantrone

Pixantrone (BBR 2778), is a novel major groove binder with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. It also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_news.htm

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pi
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
3. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
4. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
5. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
6. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
7. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
8. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
9. Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkins Lymphoma Trial
10. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
11. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)...  Genomic Health, Inc. (Nasdaq: GHDX ) ... from a health economic analysis suggesting that use of ... a significant reduction in direct medical costs and improve ... effects of unnecessary treatment.  "By providing ... measures, as demonstrated in this analysis, the Oncotype DX ...
(Date:9/12/2014)... 12, 2014 Sepsis is a life ... worldwide.  Education and awareness are fundamental to improving ... marks Sepsis Awareness Month and September 13 th ... Sepsis Alliance, "Sepsis, the body,s toxic reaction to ... every year, and thousands more are left with ...
(Date:9/11/2014)... DUBLIN, Ireland , September 11, ... ,Research and Markets ( http://www.researchandmarkets.com/research/lqkmlx/radio_frequency ) has ... Radio Frequency Identification (RFID) Market in ... Cabinets) - Industry Analysis, Size, Share, ...  report to their offering.  ,     (Logo: ...
Breaking Medicine Technology:Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics 2Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics 3Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics 4Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics 5Nanomix Supports Sepsis Awareness 2Global Radio Frequency Identification (RFID) Market in Healthcare (Tags, Readers, Middleware, Printers and Cabinets) - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2020 2Global Radio Frequency Identification (RFID) Market in Healthcare (Tags, Readers, Middleware, Printers and Cabinets) - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2020 3
... 2012 Reportlinker.com announces that a new ... catalogue: Top 200 Biopharmaceuticals ... http://www.reportlinker.com/p0572074/Top-200-Biopharmaceuticals-Industry-Report-Global.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharma The Global Biopharmaceuticals ... This report is an in-depth ...
...  Questcor Pharmaceuticals, Inc. (NASDAQ:   QCOR) today announced ... preparing to issue a report regarding the Company,s ... statement: The Company believes that its ... requirements and industry standard practices.  Questcor markets H.P. ...
Cached Medicine Technology:Top 200 Biopharmaceuticals Industry Report (Global) 2Top 200 Biopharmaceuticals Industry Report (Global) 3Top 200 Biopharmaceuticals Industry Report (Global) 4Questcor Pharmaceuticals Issues Statement 2
(Date:9/13/2014)... Va. (PRWEB) September 13, 2014 Happiness is ... to healthier living and achieving goals. That's what LWell ... pleased to announce that Stephens, a life coach who has ... was a teenager, will present her "Happiness is a Choice" ... 6:30 p.m. , This event is being offered ...
(Date:9/13/2014)... MD (PRWEB) September 13, 2014 Deaf Awareness ... The Hearing and Speech Agency hosts a week-long ... Sign Language (ASL) as the main form of communication. ... the schedule includes an ASL film night, a yoga class, ... open to the entire community. , The schedule is as ...
(Date:9/13/2014)... (PRWEB) September 13, 2014 Motion Graphics artist ... new transition pack entitled TransPack Volume 2 exclusively for Final ... fun way to transition from one clip to the next.” ... can never have too many transition options and TransPack Volume ... TransPack Volume 2 is a package of 30 thematic transitions ...
(Date:9/13/2014)... September 13, 2014 Although it’s cooled ... into mosquito high season are the state’s southern cities ... areas. With a rise in mosquitoes carrying West ... a partnership with Dixie State University’s Dr. Barnum and ... a product called NutriVex. , NutriVex is in its ...
(Date:9/12/2014)... As low testosterone lawsuit claims continue ... two of the U.S. Food & Drug Administration (FDA) ... to discuss controversial public health issues surrounding testosterone replacement ... and the Drug Safety and Risk Management Advisory Committee ... population for testosterone replacement therapy and the potential risk ...
Breaking Medicine News(10 mins):Health News:“Happiness is a Choice” Life Coaching Seminar Open to Community 2Health News:“Happiness is a Choice” Life Coaching Seminar Open to Community 3Health News:Baltimore Nonprofit Celebrates Deaf Awareness Week 2Health News:Baltimore Nonprofit Celebrates Deaf Awareness Week 3Health News:Today a new TransPack Volume 2 transition was announced from Pixel Film Studios for Final Cut Pro X. 2Health News:Dixie State University Partners with Utah Marketing Firm and the SW Mosquito Abatement and Control District for Product Testing 2Health News:Dixie State University Partners with Utah Marketing Firm and the SW Mosquito Abatement and Control District for Product Testing 3Health News:Testosterone Lawsuit Claims Continue As FDA Holds Meeting On Health Risks Associated "Low-T" Drugs Such As AndroGel 2Health News:Testosterone Lawsuit Claims Continue As FDA Holds Meeting On Health Risks Associated "Low-T" Drugs Such As AndroGel 3Health News:Testosterone Lawsuit Claims Continue As FDA Holds Meeting On Health Risks Associated "Low-T" Drugs Such As AndroGel 4Health News:Testosterone Lawsuit Claims Continue As FDA Holds Meeting On Health Risks Associated "Low-T" Drugs Such As AndroGel 5
... Organisation (WHO) Monday hailed the progress of governments of Western ... region needed greater effort to effectively control the disease. ... of detecting at least 70 percent of TB cases and ... Maaren, regional adviser for the health body's TB programme. ...
... miniature robot that can be inserted through an incision ... body. ,Researchers from Ritsumeikan University and the ... that is controlled remotely once placed inside the body. ... centimeters (0.79 inches) in length and one in diameter. ...
... that some patients who complete bariatric surgery can develop ... deficiency, called Wernicke encephalopathy. , The researchers ... about their conclusions by extensive survey of data relating ... surgery. , The syndrome - Wernicke encephalopathy ...
... inhaled anesthetics increase the number of amyloid plaques in ... of neurodegenerative diseases like Alzheimer's. ,Roderic Eckenhoff, ... Pennsylvania's Department of Anesthesia and Critical Care, and his ... edition of Neurobiology of Aging. ,Every year ...
... hardly 29 per cent of the asthmatic children surveyed had ... as a dangerous trend for not vaccinating their kids against ... officials have warned. ,Actually it has been warned ... fall victims to pneumonia or acute respiratory disease. Inactivated flu ...
... possibly hazardous chemicals called polybrominated diphenyl ethers (PBDEs). The ... and Technology and the Environmental Protection Agency of the ... clear how dangerous these PBDEs are, though some types ... is strikingly similar to that of PCBs, which are ...
Cached Medicine News:Health News:WHO Calls for Greater Efforts to Fight TB 2Health News:Inhaled Anesthetics Accelerate the Onset of Neurodegenerative Diseases Like Alzheimer's 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: